Literature DB >> 12144618

NKT cells: potential targets for autoimmune disease therapy?

K J L Hammond1, D I Godfrey.   

Abstract

NKT cells represent a unique T cell lineage that recognize glycolipid antigens in the context of the non-classical MHC class I molecule CD1d. NKT cells are potent producers of immunoregulatory cytokines, and have been implicated in several different autoimmune diseases in mice and humans, including Type 1 diabetes, experimental autoimmune encephalomyelitis--a mouse model for multiple sclerosis, systemic lupus erythematosus, and scleroderma. This review will cover the evidence for an involvement for NKT cells in these autoimmune diseases, and discuss the potential for therapeutic manipulation of these cells as a means of preventing autoimmune disease in the clinic.

Entities:  

Mesh:

Year:  2002        PMID: 12144618     DOI: 10.1034/j.1399-0039.2002.590501.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  13 in total

Review 1.  Going both ways: immune regulation via CD1d-dependent NKT cells.

Authors:  Dale I Godfrey; Mitchell Kronenberg
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

2.  Alpha-galactosylceramide as a therapeutic agent for pulmonary Mycobacterium tuberculosis infection.

Authors:  Isabel Sada-Ovalle; Markus Sköld; Tian Tian; Gurdyal S Besra; Samuel M Behar
Journal:  Am J Respir Crit Care Med       Date:  2010-05-27       Impact factor: 21.405

3.  Synthesis and evaluation of 3''- and 4''-deoxy and -fluoro analogs of the immunostimulatory glycolipid, KRN7000.

Authors:  Ravinder Raju; Bernard F Castillo; Stewart K Richardson; Meena Thakur; Ryan Severins; Mitchell Kronenberg; Amy R Howell
Journal:  Bioorg Med Chem Lett       Date:  2009-06-06       Impact factor: 2.823

Review 4.  What rheumatologists need to know about innate lymphocytes.

Authors:  Mark A Exley; George C Tsokos; Kingston H G Mills; Dirk Elewaut; Ben Mulhearn
Journal:  Nat Rev Rheumatol       Date:  2016-09-02       Impact factor: 20.543

5.  The pro-fibrotic role of dipeptidyl peptidase 4 in carbon tetrachloride-induced experimental liver injury.

Authors:  Xin M Wang; Lauren E Holz; Sumaiya Chowdhury; Shaun P Cordoba; Kathryn A Evans; Margaret G Gall; Ana Júlia Vieira de Ribeiro; Yuan Zhou Zheng; Miriam T Levy; Denise Mt Yu; Tsun-Wen Yao; Natasa Polak; Christopher J Jolly; Patrick Bertolino; Geoffrey W McCaughan; Mark D Gorrell
Journal:  Immunol Cell Biol       Date:  2016-11-30       Impact factor: 5.126

6.  Beta-glucosylceramide: a novel method for enhancement of natural killer T lymphoycte plasticity in murine models of immune-mediated disorders.

Authors:  E Zigmond; S Preston; O Pappo; G Lalazar; M Margalit; Z Shalev; L Zolotarov; D Friedman; R Alper; Y Ilan
Journal:  Gut       Date:  2007-01       Impact factor: 23.059

Review 7.  Potential role of NKT regulatory cell ligands for the treatment of immune mediated colitis.

Authors:  Madi El Haj; Ami Ben Ya'acov; Gadi Lalazar; Yaron Ilan
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

8.  Synthesis and evaluation of an acyl-chain unsaturated analog of the Th2 biasing, immunostimulatory glycolipid, OCH.

Authors:  Geetha Velmourougane; Ravinder Raju; Gabriel Bricard; Jin S Im; Gurdyal S Besra; Steven A Porcelli; Amy R Howell
Journal:  Bioorg Med Chem Lett       Date:  2009-05-18       Impact factor: 2.823

9.  Beta-glycoglycosphingolipid-induced alterations of the STAT signaling pathways are dependent on CD1d and the lipid raft protein flotillin-2.

Authors:  Gadi Lalazar; Ami Ben Ya'acov; Dan M Livovsky; Madi El Haj; Orit Pappo; Sarah Preston; Lidya Zolotarov; Yaron Ilan
Journal:  Am J Pathol       Date:  2009-02-26       Impact factor: 4.307

10.  Immune characterization of an individual with an exceptionally high natural killer T cell frequency and her immediate family.

Authors:  A C Chan; L Serwecinska; A Cochrane; L C Harrison; D I Godfrey; S P Berzins
Journal:  Clin Exp Immunol       Date:  2009-01-22       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.